Takeda Pharmaceutical (TAK) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
02B5B8B10B12B15B18B20BQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Operating Expenses

Research And Development ExpensesSelling General And Administrative Expenses
0500M1B2B2B2B3B4B4BQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

EBITDA

EBITDA
0500M1B2B2B2B3B4B4BQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

EPS

EPSEPS Diluted
000001111Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Revenue Variation (%)

Revenue Variation
-10-6-2159121620Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
06K12K19K25K31K38K44K50KQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Revenue YoY Variation (%)

P/E Ratio
-20-68213549627690Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Income YoY Variation (%)

Operating Cash FlowCapital ExpenditureFree Cash Flow
0750M2B2B3B4B4B5B6BQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Price-to-Earning Ratio

Cash At End Of Period
0875M2B3B4B4B5B6B7BQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Income Breakdown

Total AssetsTotal Liabilities
025B50B75B100B125B150B175B200BQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Per Share Metrics

Total Current AssetsTotal Non Current Assets
025B50B75B100B125B150B175B200BQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Expense Ratios

Total Current LiabilitiesTotal Non Current Liabilities
09B18B26B35B44B52B61B70BQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025
💰 Cash Flow Statement

Operating Cash Flow

Total Stockholders Equity
08B15B22B30B38B45B52B60BQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Free Cash Flow

Debt To Equity
000001111Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025

Cash Flow to Debt Ratio

Market Cap
01T2T3T4T6T7T8T9TQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025
🏦 Balance Sheet
📈 Key Metrics